Product nameAnti-alpha A Crystallin/CRYAA antibody [EPR14125(B)]
See all alpha A Crystallin/CRYAA primary antibodies
DescriptionRabbit monoclonal [EPR14125(B)] to alpha A Crystallin/CRYAA
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human alpha A Crystallin/CRYAA aa 1-100. The exact sequence is proprietary.
Database link: P02489
- Recombinant human alpha A Crystallin/CRYAA protein (ab48778) can be used as a positive control in WB. Rat and Mouse eyeball. Y79 cells.
This product was previously labelled as alpha A Crystallin
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 40% Glycerol, 0.05% BSA, 59% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab181866 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/2000. Predicted molecular weight: 20 kDa.|
FunctionMay contribute to the transparency and refractive index of the lens.
Involvement in diseaseDefects in CRYAA are a cause of cataract autosomal dominant (ADC) [MIM:604219]. Cataract is an opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Cataract is the most common treatable cause of visual disability in childhood.
Sequence similaritiesBelongs to the small heat shock protein (HSP20) family.
modificationsO-glycosylated; contains N-acetylglucosamine side chains.
Deamidation of Asn-101 in lens occurs mostly during the first 30 years of age, followed by a small additional amount of deamidation (approximately 5%) during the next approximately 38 years, resulting in a maximum of approximately 50% deamidation during the lifetime of the individual.
Phosphorylation on Ser-122 seems to be developmentally regulated. Absent in the first months of life, it appears during the first 12 years of human lifetime. The relative amount of phosphorylated form versus unphosphorylated form does not change over the lifetime of the individual.
Cellular localizationCytoplasm. Nucleus. Translocates to the nucleus during heat shock and resides in sub-nuclear structures known as SC35 speckles or nuclear splicing speckles.
- Information by UniProt
- Acry 1 antibody
- Alpha crystallin A chain antibody
- Alpha-crystallin A chain antibody
Immunofluorescence analysis of Y79 cells fixed with acetone labeling alpha A Crystallin/CRYAA with ab181866 at 1/500 dilution followed by Goat anti rabbit IgG(Alexa Fluor®555) at 1/200 dilution and counterstained with Dapi.
All lanes : Anti-alpha A Crystallin/CRYAA antibody [EPR14125(B)] (ab181866) at 1/2000 dilution
Lane 1 : Rat eyeball
Lane 2 : Mouse eyeball
Lysates/proteins at 20 µg per lane.
All lanes : Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 20 kDa